Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-31 mimic is a synthetic microRNA precursor designed to overexpress miR-31, a microRNA that acts as a tumor suppressor in various cancers, including esophageal adenocarcinoma. In the context of esophageal cancer, miR-31 is frequently downregulated, which contributes to radioresistance by allowing for enhanced DNA repair. By mimicking endogenous miR-31, this agent downregulates several key DNA repair genes, including SMUG1, MLH1, RAD51L3 (RAD51D), and MMS19. The inhibition of these targets impairs the DNA repair efficiency of cancer cells, thereby re-sensitizing them to radiation therapy and potentially improving the pathological response to neoadjuvant chemoradiotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-31 mimic.